Mitochondrial DNA copy number and pancreatic cancer in the alpha-tocopherol beta-carotene cancer prevention study

• Published in: Cancer prevention research (Philadelphia, Pa.) Vol. 4; no. 11; pp. 1912 - 1919
• Main Authors: Lynch, Shannon M, Weinstein, Stephanie J, Virtamo, Jarmo, Lan, Qing, Liu, Chin-San, Cheng, Wen-Ling, Rothman, Nathaniel, Albanes, Demetrius, Stolzenberg-Solomon, Rachael Z
• Format: Journal Article
• Language: English
• Published: United States 01.11.2011
• Subjects: Adenocarcinoma - etiology; Adenocarcinoma - prevention & control; alpha-Tocopherol; beta Carotene; Biomarkers, Tumor - genetics; Case-Control Studies; Diabetes Complications; DNA - genetics; DNA Copy Number Variations - genetics; DNA, Mitochondrial - genetics; Double-Blind Method; Humans; Male; Middle Aged; Obesity - complications; Pancreatic Neoplasms - etiology; Pancreatic Neoplasms - prevention & control; Polymerase Chain Reaction; Prognosis; Risk Factors; Smoking - adverse effects
• ISSN: 1940-6207; 1940-6215
• DOI: 10.1158/1940-6207.capr-11-0002

Diabetes, obesity, and cigarette smoke, consistent risk factors for pancreatic cancer, are sources of oxidative stress in humans that could cause mitochondrial DNA (mtDNA) damage and increase mtDNA copy number. To test whether higher mtDNA copy number is associated with increased incident pancreatic cancer, we conducted a nested case-control study in the Alpha-Tocopherol Beta Carotene Cancer Prevention (ATBC) Study cohort of male smokers, aged 50 to 69 years at baseline. Between 1992 and 2004, 203 incident cases of pancreatic adenocarcinoma occurred (follow-up: 12 years) among participants, with whole blood samples used for mtDNA extraction. For these cases and 656 controls, we calculated ORs and 95% CIs using unconditional logistic regression, adjusting for age, smoking, and diabetes history. All statistical tests were two sided. Higher mtDNA copy number was significantly associated with increased pancreatic cancer risk (highest vs. lowest mtDNA copy number quintile, OR = 1.64, 95% CI = 1.01-2.67, continuous OR = 1.14, 95% CI 1.06-1.23), particularly for cases diagnosed during the first 7 years of follow-up (OR = 2.14, 95% CI = 1.16-3.96, P(trend) = 0.01, continuous OR = 1.21, 95% CI = 1.10-1.33), but not for cases occurring during follow-up of 7 years or greater (OR = 1.14, 95% CI = 0.53-2.45, continuous OR = 1.05, 95% CI = 0.93-1.18). Our results support the hypothesis that mtDNA copy number is associated with pancreatic cancer and could possibly serve as a biomarker for pancreatic cancer development.